NTRK3 and cancer: At the DNA level, 2 patients (2/124, 1.61%) had fusions in KRTAP4-8, KRTAP4-4 and NEFH. CCDC6-RET (2/124, 1.61%), NCOA4-RET (6/124, 4.84%), ETV6-NTRK3 (5/124, 4.03%) and TPM3-NTRK1 (1/124, 0.81%) were detected at the RNA level, and 13 were patients with cancer tissues (Fig. 1E).